Dendreon Corporation (NASDAQ: DNDN)- Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients. The Company’s product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. Its advanced product candidate is Provenge (sipuleucel-T), an active cellular immunotherapy that has completed three Phase III trials for the treatment of metastatic, castrate-resistant, (also known as androgen-independent or hormone-refractory) prostate cancer.
CEOWORLD Top 5 Analyst Calls of the Week- DNDN, INSP, MCP, SIRI, VICL
Latest posts by Megan Batchelor
- Are You Using the Right Merchant Services Provider? - September 17, 2018
- How to Identify Forex Strategies That Work - September 14, 2018
- Factors You Need to Consider When Choosing an LMS Vendor - September 14, 2018